EQS-News: Evotec and Bristol Myers Squibb thereweitern Proteomics-Partnerschaft

Hamburg, October 23, 2024:
Evotec SE (Frankfurter Wertpaperbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has discovered a breakthrough in the strategic partnership with Bristol Myers Squibb regarding the use of a molecular adhesive based on Pipeline. Much research has been done on the production of Pipeline Molecular Glue Degraders in the analysis of oncology and loosening of a 50 million program suspension. US dollar and Evotec aus. When the Grundlage potential program is executed, the operation of the Transaction is executed.

Evotec and Bristol Myers Squibb have started a strategic partner in the Bereich Proteinabbau in the year 2018 and in May 2022, but the first productive result was a much-publicized pipeline reform. It is possible that Evotec is active on the Bristol Myers Squibbs branch library components of Cereblon E3 Ligase Modulators (“CELMoDs?”). Soul of Partnership is more, the fuhrungsposition in that area has been developed and an extensive pipeline has been newly developed Molecular Glue Degraders for high quality Zielmoleküle, in die autumn for Bereiche außerhalb der Onkologie, hizuzufügen.

Dr. Cord Dohrmann, Chief Scientific Officer von Evotec, comments: “There is a very good collaboration with Bristol Myers Squibb in the field of non-medicine, in one of the best medical solutions. The uniform combination of medicines and the oral processing of molecular glue breakers is a good solution and perhaps therapeutic options. A partner with BMS has developed a new pipeline of best-in-class products and can leverage one of our joint clinical validation patient program portfolios.”

Uber Molecular Glue Breakers
Conventional Small Molecule Therapeutika works on a drug drug with the protein active action. The effect of the agonist or antagonist effect is 90% of the proteins cannot be treated with medication. Conventional small molecules that are active and retain the receptor can be used. Dadurch is typically a typical hereditary scheme, which is one of the best ways to use the best medicines.

Molecular glue breakers are compounds that contain an E3 Ubiquitin Ligase and a Soul Molecular Reform. This induzierte Wechselwirkung führt zur Ubiquitinierung and zum anschließenden Abbau the recruited Proteins. Due to the mechanism of action of molecular glues, the agonistic/antagonistic properties of proteins are not present, but the scope of the protein-rich proteins is greatly expanded. Do not use the molecular glue itself to complete the process and it can no longer accelerate the washing process and thus cause longer lasting therapeutic effects.

Über Evotec’s strategic partnership with Bristol Myers Squibb for molecular adhesives
In 2018, Evotec started a long-term strategic research and development partnership in the field of Molecular Glues with Celgene, such as Bristol Myers Squibb. Bristol Myers Squibb is one of the most advanced sources for a substance library and Cereblon E3 Ligase Modulators (CELMoDs?). This strategic alliance is the development and development of a pipeline and molecular adhesive degraders for a therapeutic indication through the useless properties of Evotec’s PanOmics and PanHunter platforms that offer AI/ML-based Wirkstoffforschungs and Entwicklungsfähigke products.

Evotec specializes in high-end proteins and transcriptions on an industrial scale, a number of possible candidates on the Grundlage to profile and extend a biological profile. The possibilities for the possible solutions for the Arzneimittelentwicklung have arisen during the Evotecs PanOmics data analysis platform PanHunter, the kürzlich as software-as-a-service (“SAAS”) has a long service life. PanHunter has found the integration and analysis of that data and the ability to analyze the most common CELMoDs? for the other Fortschritt in der Lead optimization.

Evotec started working in May 2022 with the collaboration with Bristol Myers Squibb who 8 years later had a new construction and production experience, so that the product can be produced as an excellent product in generating a number of verspchenden Pipeline with Molecular Glue Degraders.

Uber Evotec SE
Evotec is a science company with a unique history, a high-quality medicine for research, for working and for the patient who uses his machine. The multimodal platform of the Unternehmens offers a unique innovative combination of technologies, data and science solutions for the research, development and production of first-in-class and best-in-class pharmaceutical products. Evotec offers partnerships and solutions for Pipeline Co-creation of all Top 20 Pharma and more than 800 biotechnology universities, academic institutions and others Akteure des Gesundheitswesens and. Evotec is strategic in a broad spectrum of medically active indications, such as neurology, onkology and respiratory and infectious diseases. Evotecs Soul is, at that time, the global development of innovative “co-owned Pipeline” innovative therapies and has a portfolio of more than 200 properties and co-ownership of F+E projects from the frühen Research in the clinical Entwicklung. The quality amounts to more than 5,000 qualified people for Evotec. The state of affairs in Europe and the US offers highly synergistic technologies and services and works as a complementary Exzellenz cluster. Find more information on our homepage www.evotec.com and follow your Twitter account @Evotec and LinkedIn.

Zukunftsbezogene Aussagen
This press conference has had a great influence on the first impression, which has attracted attention and the note of Evotecs working papers. Wörter wie “erwarten”, “annehmen”, “schätzen”, “beabsichtigen”, “können”, “planen”, “potenziell”, “sollen”, “abzielen”, “würde”, anyway Abwandlungen dieser Wörter and ähnliche Ausdrücke were Used, a zukunftsbezogene Aussagen to identify. Solche Aussagen schließen Comments op Evotecs Erwartungen für Umsätze, Konzern-EBITDA und unverpartnerte F+E-Aufwendungen ein. These cuts are based on the information, the Evotec zum Zeitpunkt der Aussage zugänglich were, anyway auf Erwartungen and Annahmen, the Evotec zu diesem Zeitpunkt for angemessen erachtet hat. The guideline values ​​that exist can no longer be stated with certainty. These excessive risks and risks on one of the Annahmen and Schätzungen, which are inherent in insecurity and independence, can prevent the control from lying by Evotec. Evotec has not used the lighting necessary to perform the display of Evotec in the background or to make a new start, to use the wiring or the stand, or to perform or activate them in order to revise them.

For more information, please read:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
[email protected]

Media

Susanne Kreuter
VP Head of Strategic Marketing
[email protected]